Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
positive symbols : Bmy save search
Perspective Therapeutics Announces Clinical Collaboration Agreement with Bristol Myers Squibb to Evaluate [(212)Pb]VMT01 in Combination with Nivolumab in MC1R-Positive Metastatic Melanoma
Published: 2024-03-18 (Crawled : 12:00) - globenewswire.com
BMY | $48.56 0.54% 1.8M
|
Health Technology
|
| O: 0.46%
H: 0.23%
C: -1.88%
vmt01 melanoma nivolumab collaboration therapeutics agreement
U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Application for Augtyro™ (repotrectinib) for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors
Published: 2024-02-14 (Crawled : 15:00) - biospace.com/
BMY | $48.56 0.54% 1.8M
|
Health Technology
|
| O: 0.23%
H: 0.44%
C: 0.14%
drug review food tumors treatment application advanced
Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy Abecma (idecabtagene vicleucel) in Earlier Lines of Therapy for Triple-Class Exposed Relapsed and Refractory Multiple Myeloma
Published: 2024-01-26 (Crawled : 15:30) - biospace.com/
BMY | $48.56 0.54% 1.8M
|
Health Technology
|
| O: 0.71%
H: 0.48%
C: -0.52%
chmp positive cell therapy
Zai Lab Announces The New England Journal of Medicine Publication Demonstrating Durable Clinical Activity of Repotrectinib in Patients with Advanced ROS1 Fusion-Positive NSCLC
Published: 2024-01-10 (Crawled : 00:00) - biospace.com/
BMY | $48.56 0.54% 1.8M
|
Health Technology
|
| O: -0.16%
H: 0.09%
C: -1.05%
ZLAB | News | $14.125 -0.67% 45K
|
Health Technology
|
| O: 0.38%
H: 1.24%
C: -2.14%
publication advanced
European Medicines Agency Validates Bristol Myers Squibb’s Application for Repotrectinib for the Treatment of Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer and NTRK-Positive Solid Tumors
Published: 2024-01-02 (Crawled : 14:00) - biospace.com/
BMY | $48.56 0.54% 1.8M
|
Health Technology
|
| O: 0.27%
H: 3.89%
C: 2.55%
lung tumors cancer cell treatment application advanced
Mirati Therapeutics Receives Positive Opinion from CHMP for KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation Following a Re-Examination Procedure
Published: 2023-11-10 (Crawled : 12:30) - prnewswire.com
BMY | $48.56 0.54% 1.8M
|
Health Technology
|
| O: 0.4%
H: 0.18%
C: 0.0%
MRTX | $58.7 -0.17% 0.34% 0
|
Health Technology
|
| O: -0.11%
H: 0.0%
C: 0.0%
krasg12 lung chmp positive cancer cell treatment therapeutics
Updated Data from TRIDENT-1 Trial Show Durable Efficacy Benefits with Repotrectinib for Patients with Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer
Published: 2023-08-16 (Crawled : 18:00) - biospace.com/
BMY | $48.56 0.54% 1.8M
|
Health Technology
|
| O: -0.66%
H: 0.46%
C: -0.67%
lung cancer cell trial show benefits
Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for Opdivo (nivolumab) as an Adjuvant Treatment for Patients with Completely Resected Stage IIB or IIC Melanoma
Published: 2023-07-21 (Crawled : 12:20) - biospace.com/
BMY | $48.56 0.54% 1.8M
|
Health Technology
|
| O: 0.19%
H: 1.41%
C: 1.24%
melanoma chmp opdivo approval positive treatment
U.S. Food and Drug Administration Approves Addition of Positive Data from Phase 3 VALOR-HCM Study to CAMZYOS® (mavacamten) Label
Published: 2023-06-16 (Crawled : 10:00) - biospace.com/
BMY | $48.56 0.54% 1.8M
|
Health Technology
|
| O: 0.32%
H: 2.1%
C: 1.97%
camzyos drug label food positive study
U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Application for Repotrectinib for the Treatment of Patients with Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer
Published: 2023-05-30 (Crawled : 12:00) - biospace.com/
BMY | $48.56 0.54% 1.8M
|
Health Technology
|
| O: -0.71%
H: 1.14%
C: 0.54%
lung drug review food cancer cell treatment application
SELLAS Announces Publication of Positive GPS Clinical Data in Ovarian Cancer in Peer Reviewed Journal
Published: 2023-03-07 (Crawled : 14:00) - globenewswire.com
BMY | $48.56 0.54% 1.8M
|
Health Technology
|
| O: 0.41%
H: 0.04%
C: -1.71%
SLS | $1.5 -1.32% 530K
|
Health Technology
|
| O: 3.82%
H: 1.23%
C: -4.91%
positive cancer publication ovarian cancer
Bristol Myers Squibb Receives Positive CHMP Opinion for Reblozyl® (luspatercept) for Adult Patients with Anemia-Associated, Non-Transfusion-Dependent (NTD) Beta Thalassemia
Published: 2023-01-27 (Crawled : 13:00) - biospace.com/
BMY | $48.56 0.54% 1.8M
|
Health Technology
|
| O: 0.0%
H: 0.63%
C: -0.74%
reblozyl chmp positive
Bristol Myers Squibb Announces Positive CHMP Opinion for Once-Daily Sotyktu (deucravacitinib) as a Treatment for Adults With Moderate-to-Severe Plaque Psoriasis
Published: 2023-01-27 (Crawled : 13:00) - biospace.com/
BMY | $48.56 0.54% 1.8M
|
Health Technology
|
| O: 0.0%
H: 0.63%
C: -0.74%
AMGN | $265.32 0.98% 550K
|
Health Technology
|
| O: -0.0%
H: 0.25%
C: -0.48%
treatment chmp psoriasis positive
Bristol Myers Squibb Announces Positive Topline Results of Phase 3 COMMANDS Trial
Published: 2022-10-31 (Crawled : 16:00) - biospace.com/
BMY | $48.56 0.54% 1.8M
|
Health Technology
|
| O: -0.31%
H: 2.7%
C: 1.15%
topline trial positive results
Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for LAG-3-Blocking Antibody Combination Opdualag (nivolumab and relatlimab) for Treatment of Patients with Unresectable or Metastatic Melanoma
Published: 2022-07-22 (Crawled : 12:20) - biospace.com/
BMY | $48.56 0.54% 1.8M
|
Health Technology
|
| O: 0.29%
H: 0.49%
C: -0.41%
treatment melanoma antibody chmp approval positive nivolumab
Purple Biotech Announces the Initiation of Phase 2 Study for CM24 in 2L PDAC PatientsDecision based on positive interim Phase 1b data in pancreatic ductal adenocarcinoma (PDAC)
Published: 2022-05-18 (Crawled : 13:20) - biospace.com/
BMY | $48.56 0.54% 1.8M
|
Health Technology
|
| O: 1.57%
H: 0.0%
C: 0.0%
cm24 biotech purple positive pancreatic phase 2 phase 2b
Purple Biotech Presents Positive Interim Phase 1b Study Results for CM24 at the American Association of Cancer Research 2022 Annual Meeting
Published: 2022-04-11 (Crawled : 12:00) - globenewswire.com
PPBT | $0.461 22K
|
Manufacturing
|
| O: -4.28%
H: 0.0%
C: -26.84%
BMY | $48.56 0.54% 1.8M
|
Health Technology
|
| O: -0.09%
H: 0.55%
C: -1.54%
cm24 research biotech positive results cancer phase 2b
Exelixis’ Partner Ipsen Receives Positive CHMP Opinion for CABOMETYX® (cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer
Published: 2022-03-25 (Crawled : 14:00) - biospace.com/
TAK | News | $13.255 0.72% 200K
|
Health Technology
|
| O: -0.53%
H: 0.57%
C: 0.34%
BMY | $48.56 0.54% 1.8M
|
Health Technology
|
| O: 1.21%
H: 0.0%
C: 0.0%
EXEL | $22.41 -0.36% 530K
|
Health Technology
|
| O: 0.14%
H: 1.53%
C: 1.48%
cabometyx positive cancer chmp
Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo (nivolumab)
Published: 2022-02-25 (Crawled : 13:00) - biospace.com/
BMY | $48.56 0.54% 1.8M
|
Health Technology
|
| O: 0.8%
H: 0.0%
C: 0.0%
opdivo positive chmp nivolumab
Bristol Myers Squibb Announces Positive Topline Results from Phase 3 VALOR-HCM Trial, Evaluating Mavacamten in Patients with Obstructive Hypertrophic Cardiomyopathy
Published: 2022-02-16 (Crawled : 12:30) - biospace.com/
BMY | $48.56 0.54% 1.8M
|
Health Technology
|
| O: 0.0%
H: 0.91%
C: -0.25%
cardio trial mavacamten topline results positive topline phase 3
Gainers vs Losers
| 79% | 21% |
Top 10 Gainers
AGBA | News | $1.22 205.0% 86M
|
Finance
EGOX | $0.0606 68.33% 250M
|
NVFY | $3.45 63.51% 20M
|
Consumer Durables
ZCMD | $1.98 36.55% 27M
|
Commercial Services
CHRO | $1.66 35.51% 70K
|
n/a
INDO | $5.43 33.09% 10M
|
Energy Minerals
PAPL | $2.07 26.22% 550K
|
RWOD | $10.08 26.05% 5.6M
|
n/a
AULT | $0.304 25.57% 47M
|
Manufacturing
HUSA 4 | $2.07 23.95% 2.1M
|
Energy Minerals
Your saved searches
Save your searches and get alerts when important news are released.